Article Information
History
- April 12, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Alyaa M. Abdel-Haleem1,*,
- Ellen Casavant2,*,
- Balazs Toth3,
- Edmond Teng4,
- Cecilia Monteiro4,
- Nikhil J. Pandya5,
- Casper C. Hoogenraad6,
- Brad A. Friedman7,
- Felix L. Yeh2,#,
- Veronica G. Anania# and
- Gloriia Novikova7,#
- 1Roche Informatics, F. Hoffmann-La Roche Ltd., ON, Canada
- 2Dept. of Translational Medicine, Genentech, Inc., South San Francisco, CA 94080, USA
- 3Genentech, Inc., South San Francisco, CA 94080, USA
- 4Department of Early Clinical Development-OMNI, Genentech, Inc., South San Francisco, CA 94080, USA
- 5Human Pathobiology & OMNI Reverse Translation, Genentech, Inc., South San Francisco, CA 94080, USA
- 6Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA
- 7gRED Computational Sciences, Genentech, Inc., South San Francisco, CA 94080, USA
- ↵#Co-corresponding; email: novikovg{at}gene.com
Posted April 12, 2024.
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures
